医学临床研究
   Jul. 13, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2022, Vol. 39 Issue (12): 1796-1798    DOI: 10.3969/j.issn.1671-7171.2022.12.011
Current Issue | Archive | Adv Search |
Risk Factors of Late-Onset Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation in Children
SONG Na, ZHANG Ben-shan, ZHENG Min-cui, et al
Hematology Department of Hunan Childrens Hospital,Changsha Hunan 410007
Download: PDF (1187 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】To retrospectively analyze the risk factors of late onset hemorrhagic cystitis (LOHC) in children with allogeneic hematopoietic stem cell transplantation (Allo-HSCT). 【Methods】The clinical data of 140 children treated with Allo-HSCT in our hospital from October 2018 to August 2022 were retrospectively analyzed, and their clinical characteristics were analyzed. Logistic regression analysis was used to analyze the related risk factors of Allo-HSCT with delayed hemorrhagic cystitis. 【Results】Among 140 patients receiving allogeneic hematopoietic stem cell transplantation, 36 patients developed hemorrhagic cystitis (25.71%). The occurrence time was 7-116 days after transplantation, and the median time was 30 days after transplantation. The duration varies from 4 to 60 days, with a median of 11 days. Two patients died due to other serious transplantation related complications at the same time, and 34 patients achieved complete remission. Allo-HSCT patients with treatment schemes including cetipar, aGVHD and CMV after transplantation had a higher probability of LOHC (P<0.05). Logistic regression analysis showed that pretreatment with Thiotepa and cytomegalovirus were independent risk factors for LOHC in Allo-HSCT patients. 【Conclusion】Pretreatment regimen containing Thiotepa and cytomegalovirus (CMV) after transplantation are independent risk factors for LOHC.
Key wordsHematopoietic Stem Cell Transplantation      Cystitis/CO      Risk Factors     
Received: 24 October 2022     
PACS:  R457.7  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Cite this article:   
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.12.011     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I12/1796
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech